Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Eastern Cooperative Oncology Group
Roswell Park Cancer Institute
Mayo Clinic
University of Michigan Rogel Cancer Center
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Eastern Cooperative Oncology Group
St. Jude Children's Research Hospital
Children's Oncology Group
University of Florida
Pediatric Brain Tumor Consortium
Mayo Clinic
BPGbio
NRG Oncology
Augusta University
OHSU Knight Cancer Institute
City of Hope Medical Center
Sun Yat-sen University
St. Jude Children's Research Hospital
Karolinska Institutet
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ohio State University Comprehensive Cancer Center
University of Iowa
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Children's Oncology Group
Polaris Group
Medical College of Wisconsin
NRG Oncology
Duke University
Alliance for Clinical Trials in Oncology
Pfizer
University of Sydney
Heinrich-Heine University, Duesseldorf
University of California, San Diego
University of Birmingham
Gustave Roussy, Cancer Campus, Grand Paris